Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benralizumab + mometasone furoate
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intranasal
01
Overview
Benralizumab + mometasone furoate is a combination of two drugs under investigation for the treatment of severe bilateral nasal polyposis in adults who remain symptomatic despite standard therapy. Benralizumab is a humanized, afucosylated monoclonal antibody (IgG1, kappa) that targets the interleukin 5 receptor alpha (IL‑5Rα) on eosinophils, leading to their rapid and near-complete depletion via antibody-dependent cell-mediated cytotoxicity (ADCC). This reduces inflammation driven by eosinophils. Mometasone furoate is a potent synthetic corticosteroid with high affinity for the glucocorticoid receptor; it exerts anti-inflammatory effects by modulating gene expression and inhibiting pro-inflammatory cytokines such as interleukins 4 and 5. The combination aims to provide an additional therapeutic option for patients with severe nasal polyps not controlled by current treatments[4][5][6].
- Brand names
- DuleraElocomRyaltrisSinuvaZenhale
02
Targets
IL5RA (Interleukin-5 receptor subunit alpha)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on benralizumab + mometasone furoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benralizumab + mometasone furoate.